“The first malaria treatment for babies has been approved by the World Health Organization, opening the door to widespread use around the globe.

In parts of Africa, up to 18% of children under six months will be infected with malaria, but there has historically been no safe treatment for the smallest of them. There were 610,000 deaths from malaria in 2024, about three quarters of which were under-fives in Africa…

Medical leaders hope that Coartem Baby, which can be used to treat infants as small as 2kg (4.4lb), will fill the treatment gap. The drug comes as sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk…

Coartem Baby now has WHO prequalification, which indicates it meets international standards of quality, safety and efficacy, and will enable public-sector procurement for many countries with high rates of malaria, particularly in sub-Saharan Africa.”

From The Guardian.

“The U.S. Nuclear Regulatory Commission (NRC) has proposed a sweeping new licensing framework designed to push microreactors out of the lab and onto the grid at unprecedented speed. The proposed rule, called Part 57, is paired with a broader agency overhaul that earlier this year created the Office of Advanced Reactors (OAR), headed by longtime NRC official Jeremy S. Bowen. Together, the two moves represent the most significant shift in U.S. nuclear regulation in a generation—a direct response to White House Executive Order 14300 (Ordering the Reform of the Nuclear Regulatory Commission) and the bipartisan Accelerating Deployment of Versatile, Advanced Nuclear for Clean Energy (ADVANCE) Act.

Announced April 24, the proposed Part 57 rule creates a streamlined, risk-informed pathway for licensing microreactors and other reactors with comparable risk profiles. The NRC and industry estimate it will save between $3.76 billion and $11.84 billion, depending on discount rate, largely by ‘reducing exemption requests and streamlining reviews.’ Construction permit and operating license timelines could shrink to six months to a year.”

From POWER magazine.

“Federal fishery managers voted Sunday to open waters off the coast of California to commercial salmon fishing for the first time since 2022, with the population rebounding after wet winters ended a long drought.

The decision by the Pacific Fishery Management Council to allow limited commercial and recreational salmon fishing off the coast is a win for the state’s salmon fishing industry, which has grappled with years of season closures due to dwindling fish stocks. The council, which manages fisheries off the West Coast, barred commercial salmon fishing off California for the past three years. It voted last year to allow some recreational fishing for the first time since 2022.”

From Associated Press.

“The U.S. Food and Drug Administration (FDA) has approved the first-ever gene therapy for inherited deafness.

The therapy, called Otarmeni, is approved to treat a form of hearing loss caused by mutations in the OTOF gene, which codes for a protein called otoferlin. Cells in the inner ear need otoferlin to translate vibrations into signals that can be interpreted by the brain. When people carry two defective copies of the OTOF gene — one from each parent — this line of communication between the inner ear and brain is cut, resulting in severe-to-profound hearing loss.

Otarmeni is a one-time treatment that uses harmless viruses to deliver working copies of OTOF into the ear. In a trial including 20 participants, 16 showed improved hearing within six months, and one additional person showed improvement within a year of treatment.”

From Live Science.